Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID ΔM2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2017
At a glance
- Drugs RSV MEDI deltaM2-2 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- 17 Jul 2017 Status changed from active, no longer recruiting to completed.
- 19 Jun 2017 Planned primary completion date changed from 1 Jul 2017 to 30 Jun 2017.
- 14 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Jul 2017.